Table 1.

Comparison of Anti-TNF vs VDZ Cohorts after Propensity Score Matching

Variables	Anti-TNF Patients	Vedolizumab Patients	P-value
Age, years (mean)	37.8	39.0	0.569
Sex, female (%)	41.3%	43.6%	0.751
Disease type
Ulcerative Colitis (%)	41.3%	43.6%	0.828
Crohn’s Disease (%)	55.4%	48.9%
Indeterminate Colitis (%)	3.3%	7.5%
Operative characteristics
Laparoscopic bowel resection with ostomy	21.7%	30.9%	0.160
Open bowel resection with ostomy	32.6%	30.9%	0.798
Laparoscopic bowel resection with anastomosis	10.9%	7.5%	0.421
Open bowel resection with anastomosis	34.8%	30.9%	0.570
Systemic corticosteroids
Within 30 days surgery (%)	52.1%	45.8%	0.383
Cumulative steroid days (mean)	158.7	167.5	0.743
Immunomodulator (%)	10.9%	13.3%	0.542
Chronic Opioid Use (%)*	63.0%	61.6%	0.737
Charlson Comorbidity Index (mean, median)	1.4, 1	1.7, 1	0.257
Malnutrition (%)	50.0%	52.1%	0.773
Hemoglobin (g/dL) (mean) [median]	12.7 [12.6]	12.3 [12.4]	0.454
Albumin (g/dL) (mean) [median]	3.8 [4.0]	3.5 [3.9]	0.503

^*Chronic opioid use was defined ≥3 separate opioid drug claims on distinct dates within a 2-year rolling window, as previously shown.⁴⁹